vTv Therapeutics (VTVT) Stock Price, News & Analysis

Company Overview

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Key Stats

• Today's Range: $16.40 to $17.37
• 50-Day Range: $13.48 to $22.74
• 52-Week Range: $12.12 to $29.19
• Volume: 4,163 shs
• Average Volume: 22,663 shs
• Market Capitalization: $52.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.00
• Consensus Rating: Buy

vTv Therapeutics Stock Analysis - MarketRank™

vTv Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 762nd out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

vTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

vTv Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of vTv Therapeutics is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of vTv Therapeutics is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.66% of the float of vTv Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

vTv Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in vTv Therapeutics has recently increased by 1.66%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

vTv Therapeutics does not currently pay a dividend.

Dividend Growth

vTv Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.66% of the float of vTv Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

vTv Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in vTv Therapeutics has recently increased by 1.66%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.67

News Sentiment

vTv Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for vTv Therapeutics this week, compared to 1 article on an average week.

Search Interest

3 people have searched for VTVT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, vTv Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.34% of the stock of vTv Therapeutics is held by insiders.

Percentage Held by Institutions

Only 17.51% of the stock of vTv Therapeutics is held by institutions.

VTVT Stock Analysis - Frequently Asked Questions

How have VTVT shares performed this year?

vTv Therapeutics' stock was trading at $13.81 at the beginning of the year. Since then, VTVT stock has increased by 18.8% and is now trading at $16.40.
View the best growth stocks for 2025 here.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc. (NASDAQ:VTVT) announced its earnings results on Thursday, March, 20th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.32. The biotechnology company had revenue of $0.02 million for the quarter.

When did vTv Therapeutics' stock split?

Shares of vTv Therapeutics reverse split on Tuesday, November 21st 2023. The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did vTv Therapeutics IPO?

vTv Therapeutics (VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

How do I buy shares of vTv Therapeutics?

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of vTv Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that vTv Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), NIO (NIO), VBI Vaccines (VBIV), Vaxart (VXRT) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 3/20/2025
• Today: 4/01/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VTVT
• CIK: 1641489
• Web: www.vtvtherapeutics.com
• Phone: (336) 841-0300
• Fax: 336-841-0310
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $35.00
• High Stock Price Target: $35.00
• Low Stock Price Target: $35.00
• Potential Upside/Downside: +107.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,250,000.00
• Net Margins: N/A
• Pretax Margin: -2,260.90%
• Return on Equity: -184.64%
• Return on Assets: -47.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.69
• Quick Ratio: 6.69

Sales & Book Value

• Annual Sales: $1.02 million
• Price / Sales: 53.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($9.27) per share
• Price / Book: -1.82

Miscellaneous

• Outstanding Shares: 3,190,000
• Free Float: 3,147,000
• Market Cap: $53.93 million
• Optionable: Not Optionable
• Beta: 1.07